Therapeutics Hormonal Agents

Effect of progesterone administration on the prognosis of patients with severe traumatic brain injury: a meta-analysis of randomized clinical trials

Pan ZY, Zhao YH, Huang WH, Xiao ZZ, Li ZQ

Published January 11, 2019 Drug Design, Development and Therapy
DOI 10.2147/DDDT.S192633 PMID 30666088 PMC PMC6333322

RRM Academy Synopsis

Progesterone lowered deaths after severe brain injury within 3 months

In a 2019 meta-analysis of eight randomized trials of 2,251 patients with severe traumatic brain injury, progesterone was linked to fewer deaths and better neurologic outcomes within 3 months. The differences did not persist at 6 months. Benefit appeared with intramuscular delivery and was absent with intravenous delivery.

Key Findings

  • Within 3 months, mortality was lower with progesterone than placebo (RR =0.59; 95% CI [0.42–0.81], P=0.001), and neurologic outcomes were better (RR =1.51; 95% CI [1.12–2.02], P=0.007).
  • At 6 months, mortality (RR =0.96; 95% CI [0.65–1.41], P=0.83) and neurologic outcomes (RR =1.09; 95% CI [0.93–1.27], P=0.31) looked similar in both groups.
  • By route, neurologic outcomes were better only with intramuscular progesterone (RR =1.61, 95% CI [1.19–2.18], P=0.002); intravenous administration showed no benefit (RR =0.99, 95% CI [0.91–1.07], P=0.75).
  • Excluding the Xiao et al study, which carried a weight of 52.7%, left the 3-month neurologic result no longer significant (RR =1.48; 95% CI [0.96–2.29], P=0.08).

Interpretation

The authors searched databases to September 1, 2018 and pooled randomized trials that compared progesterone with placebo or no progesterone. Participants were older than 15 with severe injury, and treatment began within 24 hours. The authors note that eight studies is a small number and that unpublished neutral studies could make the results look stronger.

RRM Context

Restorative reproductive medicine treats progesterone as a hormone with whole-body roles. The authors describe it as made by the ovaries and placenta and by nerve and glial cells, with preclinical effects on brain swelling and the blood–brain barrier. These trials add human outcome data.

Abstract

Purpose

The aim of this study was to assess the neuroprotective effect of progesterone administration on severe traumatic brain injury (TBI) for different follow-up periods and administration route by completing a meta-analysis of randomized clinical trials (RCTs).

Methods

A systematic literature search of PubMed, Embase, and Cochrane databases and the Web of Science (from establishment of each to September 1, 2018) was performed to identify original RCTs that evaluated the associations between progesterone treatment and the prognosis of patients with severe TBI.

Results

Eight RCTs enrolling 2,251 patients with severe TBI were included. Within 3 months post-injury, patients with progesterone administration had a lower mortality (risk ratio [RR] =0.59; 95% CI [0.42-0.81], P=0.001) and better neurologic outcomes (RR =1.51; 95% CI [1.12-2.02], P=0.007) than those who received placebo. However, these differences did not persist at 6 months post-injury for mortality (RR =0.96; 95% CI [0.65-1.41], P=0.83) or neurologic outcomes (RR =1.09; 95% CI [0.93-1.27], P=0.31). The analysis stratified by administration route showed that beneficial effects were only observed in patients who received progesterone intramuscularly (RR =1.61, 95% CI [1.19-2.18], P=0.002); no benefit was observed with intravenous administration (RR =0.99, 95% CI [0.91-1.07], P=0.75).

Conclusion

Progesterone administration improved the clinical outcomes of severe TBI patients within 3 months but may not have significant long-term benefits 6 months post-injury.

Topics

Related research

Therapeutics › Hormonal Agents › Progesterone and Progestins
Zhi-Yong Pan, Yu-Hang Zhao, Wen-Hong Huang, Zhi-Ze Xiao, Zhi-Qiang Li
Z Pan, Y Zhao, W Huang, Z Xiao, Z Li
PMID 30666088 30666088 DOI 10.2147/DDDT.S192633 10.2147/DDDT.S192633 Pan et al. 2019, Pan 2019